EUVIMEDEUVIMED entdecken
Open Access

Pretreatment and acquired HIV drug resistance in Belize—results of nationally representative surveys, 2021–22

Francis Morey, Amalia Girón-Callejas, Russell Manzanero, Aspiro Urbina, Claudia García-Morales, Job Joseph, Edwin Bolastig, Sandra Jones, Stephanie M Wu, Daniela Tapia-Trejo, Jessica Monreal-Flores, Veronica Ortega und 6 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Francis Morey und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Services and Allied Health, Ministry of Health and Wellness, Belmopan, Belize. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Programa Presupuestal P016; Anexo 13 del Decreto del Presupuesto de Egresos de la Federación, Tuberculosis and Malaria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rising prevalence of pretreatment drug resistance (PDR) to non-nucleoside reverse-transcriptase inhibitors threatens the effectiveness of ART. In response, the WHO recommends dolutegravir-based ART regimens due to their high genetic barrier to resistance and better treatment outcomes. This is expected to contribute to achieving the Joint United Nations Programme on HIV/AIDS (UNAIDS) target of 95% viral suppression in people on ART.

Objectives

To estimate the prevalence of PDR among adults initiating ART and assess viral suppression and acquired HIV drug resistance (ADR) among individuals receiving ART in Belize. Patients and methods Nationally representative cross-sectional PDR and ADR surveys were conducted between 2021 and 2022. Sixty-seven adults were included in the PDR survey, and 43 children and adolescents and 331 adults were included in the ADR survey. Demographic and clinic data and blood specimens were collected. HIV drug resistance (HIVDR) was predicted using the Stanford HIVdb tool.

Results

The prevalence of PDR to efavirenz or nevirapine in adults was 49.3% (95% CI 42.2%–56.4%) and was significantly higher in those with previous antiretroviral exposure (OR: 7.16; 95% CI 2.71–18.95; P = 0.002). Among children and adolescents receiving ART, 50.0% had viral suppression, with better rates for those receiving dolutegravir-based ART (OR: 5.31; 95% CI 3.02–9.34; P < 0.001). In adults, 79.6% achieved viral suppression. No resistance to integrase inhibitors was observed in those on dolutegravir-based ART.

Conclusions

Prioritizing dolutegravir-based ART is critical for achieving HIV epidemic control in Belize. Efforts should focus on retention in care and adherence support to prevent HIVDR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralAnti-HIV AgentsHumansMaleAdultFemaleCross-Sectional StudiesAdolescentYoung AdultMiddle AgedChildBelizePrevalencePyridonesHeterocyclic Compounds, 3-RingAlkynesOxazinesCyclopropanesBenzoxazinesHIV-1PiperazinesNevirapine

Substanzen

Anti-HIV AgentsPyridonesHeterocyclic Compounds, 3-RingAlkynesOxazinesCyclopropanesBenzoxazinesPiperazinesNevirapineDolutegravir

Autor:innen und Institutionen

  • Hospital Services and Allied Health, Ministry of Health and Wellness, Belmopan, Belize.
  • Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City 14080, Mexico.
  • Epidemiology Unit, Ministry of Health and Wellness, Belmopan, Belize.
  • Department of Communicable Diseases Prevention, Control and Elimination, Pan-American Health Organization, World Health Organization (WHO) Country Office for Belize, Belmopan, Belize.
  • Health Systems and Services, Pan-American Health Organization, World Health Organization (WHO) Country Office for Belize, Belmopan, Belize.
  • Department of Communicable Diseases Prevention, Control and Elimination, Pan-American Health Organization, World Health Organization (WHO) Regional Office for the Americas, Washington, DC 20037, USA.

Förderung

  • NIAID NIH HHS
  • Programa Presupuestal P016; Anexo 13 del Decreto del Presupuesto de Egresos de la Federación
  • Tuberculosis and Malaria
  • The Global Fund to Fight AIDS
  • Canadian Institutes for Health Research
  • Mexican Government
  • World Health Organization

Zitieren

APA

Morey, F., Girón-Callejas, A., Manzanero, R., Urbina, A., García-Morales, C., Joseph, J., Bolastig, E., Jones, S., Wu, S. M., Tapia-Trejo, D., Monreal-Flores, J., Ortega, V., Manzanero, M., Sosa, A., Ravasi, G., Jordan, M. R., Sued, O., & Ávila-Ríos, S. (2025). Pretreatment and acquired HIV drug resistance in Belize—results of nationally representative surveys, 2021–22. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae408

Vancouver

Morey F, Girón-Callejas A, Manzanero R, Urbina A, García-Morales C, Joseph J, et al. Pretreatment and acquired HIV drug resistance in Belize—results of nationally representative surveys, 2021–22. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae408

BibTeX
@article{Morey2025,
  author = {Morey, Francis and Girón-Callejas, Amalia and Manzanero, Russell and Urbina, Aspiro and García-Morales, Claudia and Joseph, Job and Bolastig, Edwin and Jones, Sandra and Wu, Stephanie M and Tapia-Trejo, Daniela and Monreal-Flores, Jessica and Ortega, Veronica and Manzanero, Marvin and Sosa, Aldo and Ravasi, Giovanni and Jordan, Michael R and Sued, Omar and Ávila-Ríos, Santiago},
  title = {Pretreatment and acquired HIV drug resistance in Belize—results of nationally representative surveys, 2021–22},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae408}
}
Kostenlos starten →